Endothelin-1 could be one of the targets of psoriasis therapy [2]

British Journal of Dermatology

Volumn 151, Issue 6, 2004, Pages 1273-1275

  Simeone, P ^a   Teson, M ^b   Latini, A ^c   Carducci, M ^c   Venuti, A ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^c SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

22 OXACALCITRIOL; ATRASENTAN; CALCIPOTRIOL; CYTOKINE; ENDOTHELIN 1; ENDOTHELIN 1 ANTAGONIST; ENDOTHELIN 1 RECEPTOR; ENDOTHELIN 2; ENDOTHELIN 3; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; G PROTEIN COUPLED RECEPTOR; GROWTH FACTOR; INTERLEUKIN 1ALPHA; RECEPTOR SUBTYPE; TACALCITOL; UNCLASSIFIED DRUG; VASCULOTROPIN; VITAMIN D DERIVATIVE;

ANGIOGENESIS; AUTOCRINE EFFECT; CELL CULTURE; CELL DIFFERENTIATION; CELL HYPERPLASIA; CELL PROLIFERATION; COMPETITIVE INHIBITION; CYTOKINE PRODUCTION; DRUG MECHANISM; DRUG RECEPTOR BINDING; EPIDERMIS CELL; HOMEOSTASIS; INFLAMMATION; KERATINOCYTE; LETTER; PATHOGENESIS; PRIORITY JOURNAL; PSORIASIS; PUNCH BIOPSY; RECEPTOR AFFINITY; RECEPTOR BLOCKING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN INFLAMMATION;

CELLS, CULTURED; DERMATOLOGIC AGENTS; ENDOTHELIN-1; HUMANS; KERATINOCYTES; PSORIASIS; PYRROLIDINES;

EID: 11144340245     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2004.06277.x     Document Type: Letter

References (11)

1. Greaves MW, Weinstein GD. Treatment of psoriasis. N Engl J Med 1995; 332: 581-8.
2. Takahashi H, Tbe M, Kinouchi M et al. Similarly potent action of 1,25-dihydroxyvitamin D3 and its analogues, tacalcitol, calcipotriol, and maxacalcitol on normal human keratinocyte proliferation and differentiation. J Dermatol Sci 2003; 31: 21-8.
3. Bagnato A, Venuti A, Di Castro V et al. Identification of the ETA receptor subtype that mediates endothelin induced autocrine proliferation of normal human keratinocytes. Biochem Biophys Res Commun 1995; 209: 80-6.
4. Venuti A, Salani D, Manni V et al. Expression of endothelin 1 and endothelin A receptor in HPV-associated cervical carcinoma: new potential targets for anticancer therapy. FASEB J 2000; 14: 2277-83.
5. Bagnato A, Cirilli A, Salani D et al. Growth inhibition of cervix carcinoma cells in vivo by endothelin A receptor blockade. Cancer Res 2002: 62: 6381-4.
6. Bonifati C, Mussi A, Carducci M et al. Serum endothelin 1 levels are increased in psoriatic patients and correlate with disease severity. Int J Immunopath Ph 1997; 10: 81-2.
7. Bonifati C, Mussi A, Carducci M et al. Endothelin-1 levels are increased in sera and lesional skin extracts of psoriatic patients and correlate with disease severity. Acta Derm Venereol (Stockh) 1998; 78: 22-6.
8. Zambruno G, Marchisio PC, Marconi A et al. Transforming growth factor-β1 modulates β1 and β5 integrin receptors and induces the de novo expression of the αvβ6 heterodimer in normal human keratinocytes: implications for wound healing. J Cell Biol 1995; 129: 853-65.
9. Salani D, Rosano L, Di Castro V et al. ABT-627, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma growth in vitro. Clin Sci 2002; 48: S318-21.
10. Carducci MA, Padley RJ, Breul J et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003; 21: 679-89.
11. Pernet I, Mayoux C, Trompezinski S et al. Modulation of endothelin-1 in normal human keratinocytes by UVA1/B radiations, prostaglandin E2 and peptidase inhibitors. Exp Dermatol 2000; 9: 401-6.